Format

Send to

Choose Destination
BMC Public Health. 2016 Mar 3;16:217. doi: 10.1186/s12889-016-2792-8.

A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation.

Author information

1
Center for the Study of Tobacco Products, Virginia Commonwealth University, 1112 East Clay Street, Suite B-08, Box 980205, Richmond, VA, 23298, USA.
2
Department of Psychology, Virginia Commonwealth University, Richmond, VA, USA.
3
Tobacco Center of Regulatory Science, Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, PA, USA.
4
Department of Public Health Sciences, Pennsylvania State University College of Medicine, Hershey, PA, USA.
5
Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, USA.
6
Center for the Study of Tobacco Products, Virginia Commonwealth University, 1112 East Clay Street, Suite B-08, Box 980205, Richmond, VA, 23298, USA. teissenb@vcu.edu.
7
Department of Psychology, Virginia Commonwealth University, Richmond, VA, USA. teissenb@vcu.edu.

Abstract

BACKGROUND:

This study is a systematic evaluation of a novel tobacco product, electronic cigarettes (ECIGs) using a two-site, four-arm, 6-month, parallel-group randomized controlled trial (RCT) with a follow-up to 9 months. Virginia Commonwealth University is the primary site and Penn State University is the secondary site. This RCT design is important because it is informed by analytical work, clinical laboratory results, and qualitative/quantitative findings regarding the specific ECIG products used.

METHODS:

Participants (N = 520) will be randomized across sites and must be healthy smokers of >9 cigarettes for at least one year, who have not had a quit attempt in the prior month, are not planning to quit in the next 6 months, and are interested in reducing cigarette intake. Participants will be randomized into one of four 24-week conditions: a cigarette substitute that does not produce an inhalable aerosol; or one of three ECIG conditions that differ by nicotine concentration 0, 8, or 36 mg/ml. Blocked randomization will be accomplished with a 1:1:1:1 ratio of condition assignments at each site. Specific aims are to: characterize ECIG influence on toxicants, biomarkers, health indicators, and disease risk; determine tobacco abstinence symptom and adverse event profile associated with real-world ECIG use; and examine the influence of ECIG use on conventional tobacco product use. Liquid nicotine concentration-related differences on these study outcomes are predicted. Participants and research staff in contact with participants will be blinded to the nicotine concentration in the ECIG conditions.

DISCUSSION:

Results from this study will inform knowledge concerning ECIG use as well as demonstrate a model that may be applied to other novel tobacco products. The model of using prior empirical testing of ECIG devices should be considered in other RCT evaluations.

TRIAL REGISTRATION:

TRN: NCT02342795 , registered December 16, 2014.

PMID:
26941050
PMCID:
PMC4778292
DOI:
10.1186/s12889-016-2792-8
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center